Literature DB >> 15194901

The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder.

Louis S Matza1, Anne M Rentz, Kristina Secnik, Andrine R Swensen, Dennis A Revicki, David Michelson, Thomas Spencer, Jeffrey H Newcorn, Christopher J Kratochvil.   

Abstract

Clinical research on attention-deficit hyperactivity disorder (ADHD) has begun to integrate measures of health-related quality of life (HRQL) as part of the overall assessment of treatment outcomes. This study examines the association between HRQL and measures of clinical symptoms of ADHD. Data were gathered from 297 children and adolescents in an 8-week, randomized, double-blind, placebo-controlled, clinical trial of atomoxetine treatment for ADHD. HRQL was assessed with the Child Health Questionnaire 50-item Parent Form. ADHD symptoms were assessed with the ADHD Rating Scale-IV; Parent Version and Clinical Global Impressions-ADHD-Severity. Associations between HRQL and clinical symptoms were assessed with correlations, analyses of variance with post hoc comparisons, and t tests. The Child Health Questionnaire 50-item Parent Form scales assessing psychosocial domains of HRQL were significantly negatively correlated with clinical measures. Improvement in clinical symptoms was associated with corresponding improvement in psychosocial aspects of HRQL. The findings suggest that HRQL instruments can add important information to efficacy measures in clinical trials of ADHD treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15194901     DOI: 10.1097/00004703-200406000-00005

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  36 in total

1.  Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition.

Authors:  Anne W Riley; David Coghill; Christopher B Forrest; Maria J Lorenzo; Stephen J Ralston; Georg Spiel
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

2.  Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience.

Authors:  Nunzia Rainone; Alessandro Chiodi; Roberta Lanzillo; Valeria Magri; Anna Napolitano; Vincenzo Brescia Morra; Paolo Valerio; Maria Francesca Freda
Journal:  Qual Life Res       Date:  2016-12-07       Impact factor: 4.147

Review 3.  Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.

Authors:  Tobias Banaschewski; David Coghill; Paramala Santosh; Alessandro Zuddas; Philip Asherson; Jan Buitelaar; Marina Danckaerts; Manfred Döpfner; Stephen V Faraone; Aribert Rothenberger; Joseph Sergeant; Hans-Christoph Steinhausen; Edmund J S Sonuga-Barke; Eric Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-05-05       Impact factor: 4.785

4.  A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.

Authors:  Daniel Y Lin; Christopher J Kratochvil; Wen Xu; Ling Jin; Deborah N D'Souza; William Kielbasa; Albert J Allen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05       Impact factor: 2.576

5.  Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Ann C Childress; Andrew J Cutler; Keith Saylor; Maria Gasior; Mohamed Hamdani; M Celeste Ferreira-Cornwell; Robert L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

6.  Longitudinal Associations between Neurodevelopment and Psychosocial Health Status in Patients with Repaired D-Transposition of the Great Arteries.

Authors:  Victoria K Robson; Christian Stopp; David Wypij; Carolyn Dunbar-Masterson; David C Bellinger; David R DeMaso; Leonard A Rappaport; Jane W Newburger
Journal:  J Pediatr       Date:  2018-09-28       Impact factor: 4.406

7.  Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.

Authors:  Ralf W Dittmann; Peter M Wehmeier; Alexander Schacht; Martin Lehmann; Gerd Lehmkuhl
Journal:  Atten Defic Hyperact Disord       Date:  2009-09-23

8.  Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Authors:  Oscar G Bukstein; L Eugene Arnold; Jeanne M Landgraf; Paul Hodgkins
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-12-10       Impact factor: 3.033

9.  Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians.

Authors:  Ralf W Dittmann; Peter M Wehmeier; Alexander Schacht; Anette Minarzyk; Martin Lehmann; Kathrin Sevecke; Gerd Lehmkuhl
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-08-24       Impact factor: 3.033

10.  Effect on health-related quality of life of changes in mental health in children and adolescents.

Authors:  Luis Rajmil; Jorge A Palacio-Vieira; Michael Herdman; Sílvia López-Aguilà; Ester Villalonga-Olives; Josep M Valderas; Mireia Espallargues; Jordi Alonso
Journal:  Health Qual Life Outcomes       Date:  2009-12-23       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.